Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema

NCT02245516 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinal Vein Occlusion
Diabetic Macular Edema

Interventions

DRUG: KPI-121 0.25% Ophthalmic Suspension
DRUG: KPI-121 1.0% Ophthalmic Suspension

Sponsor

Kala Pharmaceuticals, Inc.